Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC

Visit https://www.peervoice.com/WPN860 to view the entire programme with slides. After completing “Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC”, participants will be able to: Discuss the rationale for adjuvant therapy in the management of patients with early-stage, EGFR-mutant non–small-cell lung cancer (NSCLC); Translate current evidence for EGFR TKIs in the adjuvant setting into optimal treatment plans for patients with early-stage, EGFR-mutant NSCLC; and Identify patient and disease factors that can help guide treatment decision-making in the adjuvant setting.